<DOC>
	<DOCNO>NCT01089166</DOCNO>
	<brief_summary>Objective : To compare bioavailability Extended Release Metformin HCl Tablet ( Test formulation , Torrent Pharmaceuticals Ltd. , India ) versus Glucophage XR® Tablets ( Reference formulation , Bristol-Myers Squibb Company , USA ) Healthy Human Volunteers fast condition . Study Design : An Open-Label , Randomised , 2-Period , 2-Treatment , Crossover Study fast condition .</brief_summary>
	<brief_title>Study Compare Bioavailability Extended Release Metformin HCl Tablet Versus Glucophage XR® Tablets Healthy Human Volunteers Under Fasting Condition</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<criteria>Subjects must meet follow criterion order include study : 1 . Sex : male . 2 . Age : 18 45 year . 3 . Subject BMI 1827 ( inclusive ) kg/m2 minimum 50 kg weight . 4 . Healthy willing participate study . 5 . Subject willing adhere protocol requirement provide write informed consent . 6 . Nonsmokers smoker smoke less 10 cigarette day . The subject exclude study base follow criterion : 1 . Clinically relevant abnormality result laboratory screening evaluation . 2 . Clinically significant abnormal ECG Chest Xray . 3 . Systolic blood pressure le 100 mm Hg 140 mm Hg diastolic blood pressure le 60 mm Hg 90 mm Hg . 4 . Pulse rate le 50/minute 100/minute . 5 . Oral temperature le 95°F 98.6°F . 6 . Respiratory rate le 12/minute 20/minute 7 . Addiction alcohol history drug abuse within past 2 year . 8 . Recent History kidney liver dysfunction . 9 . History allergy test drug drug chemically similar drug investigation . 10 . Administration/ Intake prescription OTC medication two week study . 11 . Patients suffer chronic illness arthritis , asthma etc . 12 . HIV , HCV , HBsAg positive Subjects . 13 . Opioids , tetra hydrocannabinoids , amphetamine , barbiturate , benzodiazepine , Cocaine positive Subjects base urine test . 14 . Subjects suffer psychiatric ( acute chronic ) illness require medication . 15 . Administration investigational product period 0 3 month entry study . 16 . Intake barbiturate enzymeinducing drug last three month . 17 . History significant blood loss due reason , include blood donation past 12 week . The total blood loss last 3 month include study exceed 350ml . 18 . History bleed disorder . 19 . Existence surgical medical condition , , judgement Chief investigator and/or clinical investigator , might interfere absorption , distribution , metabolism excretion drug likely compromise safety Subjects . 20 . Inability communicate cooperate due language problem , poor mental development impair cerebral function .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>